BeiGenes Brutons tyrosine kinase inhibitor, Brukinsa gets China NMPA approval
By, Admin1 min read
Share
BeiGene, a global biotechnology company, announced the China National Medical Products Administration (NMPA) approved four applications for Brukinsa (zanubrutinib), the company
Found this useful? Share it with your team.
Newsletter
Stay ahead with Clival insights
Subscribe to get the latest updates, data releases and industry information — straight to your inbox.
